Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 19.06M 16.57M 15.42M 14.16M 26.73M 1.82B 27.15M 71.33M 906M 71.57M 69.99M 3.04B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.47M 36.05M 33.56M 30.81M 58.18M 3.96B 59.08M 155M 1.97B 156M 152M 6.61B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

27/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/11/23	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/10/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/10/23	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/10/23	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/10/23	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/10/23	Irras Obtains Extension for SEK20 Million Loan	MT
16/10/23	Irras extends SEK 20 million short-term loan	FW
02/10/23	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/09/23	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/05/23	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/05/23	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/02/23	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

20/10/23	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
19/10/23	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
19/10/23	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
16/10/23	IRRAS publishes prospectus	AQ
15/10/23	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	30/06/2021
Griffen Stapp DFI	Director of Finance/CFO	40	16/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	08/03/2021

IRRAS AB Share Price OTC Markets

Stocks

IRRA.F

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB

Latest news : IRRAS AB

Analysts' recommendations: IRRAS AB

Press Releases: IRRAS AB

Quotes and Performance

Managers and Directors: IRRAS AB

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	31/05/2015
Marios Fotiadis CHM	Chairman	53	17/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	31/08/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB	-15.36%	-27.68%	-	-	16.9M
STRYKER CORPORATION	-6.42%	-1.38%	-13.79%	+18.62%	125B
SMITH & NEPHEW PLC	-2.48%	+1.62%	+0.17%	+0.61%	13.12B
GLAUKOS CORPORATION	-1.07%	+8.56%	+93.50%	+123.13%	9.83B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.11%	+10.55%	-40.93%	-65.72%	4.86B
DOUBLE MEDICAL TECHNOLOGY INC.	-2.28%	-0.67%	-3.31%	+36.23%	2.61B
ENOVIS CORPORATION	-0.51%	+7.84%	+13.25%	-53.59%	1.68B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+1.24%	+5.88%	-24.84%	-31.18%	1.68B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.60%	+5.00%	-14.81%	-19.18%	1.67B
Average	-2.80%	+3.05%	+1.15%	+1.11%	20.05B
Weighted average by Cap.	-5.26%	-0.18%	-6.57%	+19.61%

	2023	2024
Net sales	42.88M 4.5M 3.91M 3.64M 3.34M 6.31M 429M 6.4M 16.83M 214M 16.88M 16.51M 716M	57.98M 6.08M 5.28M 4.92M 4.52M 8.53M 580M 8.66M 22.76M 289M 22.83M 22.33M 969M
Net income	-209M -21.9M -19.04M -17.72M -16.27M -30.72M -2.09B -31.2M -81.98M -1.04B -82.25M -80.44M -3.49B	-95.98M -10.06M -8.75M -8.14M -7.48M -14.12M -961M -14.34M -37.67M -478M -37.8M -36.97M -1.6B
Net Debt	43.85M 4.6M 4M 3.72M 3.42M 6.45M 439M 6.55M 17.21M 218M 17.27M 16.89M 733M	214M 22.42M 19.49M 18.14M 16.65M 31.45M 2.14B 31.93M 83.9M 1.07B 84.18M 82.33M 3.57B